MADISON, Wisconsin, 19 August 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and SpayVac for Wildlife, Inc. (“SpayVac”) jointly announce that SpayVac® recently completed the establishment of its new research and manufacturing facility in Madison, Wisconsin to produce their long-lasting, single-dose veterinary contraceptive vaccines.

SpayVac® uses a patented, liposome-based antigen delivery platform technology licensed from BioVaxys (https://www.biovaxys.com/) that has demonstrated a robust and sustained immune response in multiple species. SpayVac single-dose vaccines will address fertility control needs in the wildlife, livestock and aquaculture industries.

SpayVac for Wildlife, Inc. was originally founded at the University of Victoria, British Columbiaand moved to Madison, Wisconsinafter the pandemic. With support from the BrightStar Wisconsin Foundation and angel investors, SpayVac was able to expand its laboratory and lease space in a building owned by Lytic Solutions, where the company can produce vaccines for ongoing and future experimental contraception studies.

“This new lab will greatly enhance our ability to develop new vaccine formulations for species that would benefit from humane, long-term fertility control,” said Dr. Ursula Bechert, Vice President of Research and Development at SpayVac for Wildlife. Tom D’Orazio, CEO of SpayVac for Wildlife, shared, “I am excited about the many benefits of this space. It is flexible enough to accommodate both our research and small-scale manufacturing. The Lytic facility has a number of other biopharmaceutical companies as tenants, such as Kendrick Laboratories and Plumb Pharmaceuticals, creating a biotech hub and collaborative environment.”

SpayVac plans to soon launch fertility control vaccines for deer, horses and other animals, also based on the patented liposome-based delivery platform technology licensed from BioVaxys.

Kenneth Kovan, President and Chief Operating Officer of BioVaxys, said, “As our licensee SpayVac is on schedule to submit its application for regulatory approval in 2025, it expects commercial sales that will generate licensing revenue from our liposome-based antigen delivery platform technology.”

About SpayVac for Wildlife, Inc.

SpayVac for Wildlife, Inc. (https://spayvac.com/) based in Madison, Wisconsindevelops human vaccines for fertility control in animals. SpayVac’s contraceptive vaccines are effective for several years in many animal species with just a single injection. SpayVac is a combination of an active ingredient encapsulated in a proprietary lipid nanoparticle. If you have any questions about this research or SpayVac in general, please email [email protected].

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a clinical-stage biopharmaceutical company registered in British Columbia, Canadais dedicated to improving the lives of patients with novel immunotherapies based on the immune-building technology platform DPX™ and its HapTenix^© “Neoantigen” tumor cell construct platform for the treatment of cancer, infectious diseases, antigen desensitization for the treatment of food allergies and other immunological areas. The Company’s clinical pipeline includes Maveropepimut-S, a DPX™-based vaccine in Phase IIB clinical development for advanced relapsed-refractory diffuse large B-cell lymphoma (DLBCL) and platinum-resistant ovarian cancer, DPX-SurMAGE in Phase 1 for bladder cancer, DPX™-RSV in Phase 1 for respiratory syncytial virus and BVX-0918, a personalized immunotherapeutic vaccine using the Company’s proprietary HapTenix^© Tumor cell construct platform “Neoantigen”, which will soon enter Phase I of Spain for the treatment of late-stage refractive ovarian cancer. The Company is also leveraging its expertise in tumor immunology and the creation of a unique library of T lymphocytes and other data sets following vaccination with its personalized immunotherapy vaccines to use predictive algorithms and other technologies to identify new targetable tumor antigens.

BioVaxys’ common shares are listed on the CSE under the ticker symbol “BIOV” and trade on the Frankfurt Stock Exchange (FRA: 5LB) and in the United States (OTCQB: BVAXF).

ON BEHALF OF THE BOARD
Signed “James Passin”
James Passin, CEO
BioVaxys Technology Corp.
+1 646 452 7054

ON BEHALF OF THE BOARD
Signed “Dr. Ursula Bechert”
Dr. Ursula Bechert, VP Research & Development
SpayVac for Wildlife, Inc.
+1 877 510 6812

Logo: https://mma.prnewswire.com/media/2415135/4832936/BioVaxys_Technology_Corp_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/spayvac-for-wildlife-inc-announces-completion-of-spayvac-research-and-production-facility-in-madison-wisconsin-302225118.html

Never miss a story from BioVaxys Technology Corp.